173 related articles for article (PubMed ID: 17470544)
1. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.
Slepenkin A; Enquist PA; Hägglund U; de la Maza LM; Elofsson M; Peterson EM
Infect Immun; 2007 Jul; 75(7):3478-89. PubMed ID: 17470544
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.
Bailey L; Gylfe A; Sundin C; Muschiol S; Elofsson M; Nordström P; Henriques-Normark B; Lugert R; Waldenström A; Wolf-Watz H; Bergström S
FEBS Lett; 2007 Feb; 581(4):587-95. PubMed ID: 17257594
[TBL] [Abstract][Full Text] [Related]
3. Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae.
Chu H; Slepenkin A; Elofsson M; Keyser P; de la Maza LM; Peterson EM
Int J Antimicrob Agents; 2010 Aug; 36(2):145-50. PubMed ID: 20605703
[TBL] [Abstract][Full Text] [Related]
4. Analysis of putative Chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates.
Fields KA; Fischer ER; Mead DJ; Hackstadt T
J Bacteriol; 2005 Sep; 187(18):6466-78. PubMed ID: 16159780
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 3-isoxazolidone derivatives as new Chlamydia trachomatis inhibitors.
Abdelsayed S; Ha Duong NT; Hai J; Hémadi M; El Hage Chahine JM; Verbeke P; Serradji N
Bioorg Med Chem Lett; 2014 Aug; 24(16):3854-60. PubMed ID: 25027937
[TBL] [Abstract][Full Text] [Related]
6. A series of ceramide analogs modified at the 1-position with potent activity against the intracellular growth of Chlamydia trachomatis.
Saied EM; Banhart S; Bürkle SE; Heuer D; Arenz C
Future Med Chem; 2015; 7(15):1971-80. PubMed ID: 26496536
[TBL] [Abstract][Full Text] [Related]
7. Chlamydia trachomatis Type III Secretion Proteins Regulate Transcription.
Hanson BR; Slepenkin A; Peterson EM; Tan M
J Bacteriol; 2015 Oct; 197(20):3238-44. PubMed ID: 26216849
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells.
Muschiol S; Normark S; Henriques-Normark B; Subtil A
BMC Microbiol; 2009 Apr; 9():75. PubMed ID: 19383140
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of novel polypharmacological antichlamydial agents.
Sunduru N; Salin O; Gylfe Å; Elofsson M
Eur J Med Chem; 2015 Aug; 101():595-603. PubMed ID: 26204507
[TBL] [Abstract][Full Text] [Related]
10. In vitro antichlamydial activity of garenoxacin against Chlamydia trachomatis.
Futakuchi N; Nakatani M; Takahata M; Mitsuyama J
J Infect Chemother; 2012 Aug; 18(4):428-35. PubMed ID: 22113367
[TBL] [Abstract][Full Text] [Related]
11. Effects of sustained antibiotic bactericidal treatment on Chlamydia trachomatis-infected epithelial-like cells (HeLa) and monocyte-like cells (THP-1 and U-937).
Mpiga P; Ravaoarinoro M
Int J Antimicrob Agents; 2006 Apr; 27(4):316-24. PubMed ID: 16527461
[TBL] [Abstract][Full Text] [Related]
12. Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.
Engström P; Nguyen BD; Normark J; Nilsson I; Bastidas RJ; Gylfe A; Elofsson M; Fields KA; Valdivia RH; Wolf-Watz H; Bergström S
J Bacteriol; 2013 Sep; 195(18):4221-30. PubMed ID: 23852872
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol Inhibits Propagation of
Petyaev IM; Zigangirova NA; Morgunova EY; Kyle NH; Fedina ED; Bashmakov YK
Biomed Res Int; 2017; 2017():4064071. PubMed ID: 29318147
[TBL] [Abstract][Full Text] [Related]
14. Biosynthesized tea polyphenols inactivate Chlamydia trachomatis in vitro.
Yamazaki T; Kishimoto T; Shiga S; Sato K; Hagiwara T; Inoue M; Sasaki N; Ouchi K; Hara Y
Antimicrob Agents Chemother; 2005 Jun; 49(6):2501-3. PubMed ID: 15917555
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle.
Wolf K; Betts HJ; Chellas-Géry B; Hower S; Linton CN; Fields KA
Mol Microbiol; 2006 Sep; 61(6):1543-55. PubMed ID: 16968227
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Assessment of 3-Substituted Phenazines as Novel Antichlamydial Agents.
Bao X; Liu Z; Ni M; Xia C; Xu S; Yang S; Zhao Y
Med Chem; 2020; 16(3):413-421. PubMed ID: 31284867
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis.
Muschiol S; Bailey L; Gylfe A; Sundin C; Hultenby K; Bergström S; Elofsson M; Wolf-Watz H; Normark S; Henriques-Normark B
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14566-71. PubMed ID: 16973741
[TBL] [Abstract][Full Text] [Related]
18. Gamma interferon-induced nitric oxide production reduces Chlamydia trachomatis infectivity in McCoy cells.
Mayer J; Woods ML; Vavrin Z; Hibbs JB
Infect Immun; 1993 Feb; 61(2):491-7. PubMed ID: 8423078
[TBL] [Abstract][Full Text] [Related]
19. Interaction between components of the type III secretion system of Chlamydiaceae.
Slepenkin A; de la Maza LM; Peterson EM
J Bacteriol; 2005 Jan; 187(2):473-9. PubMed ID: 15629918
[TBL] [Abstract][Full Text] [Related]
20. Affinities of beta-lactams for penicillin binding proteins of Chlamydia trachomatis and their antichlamydial activities.
Storey C; Chopra I
Antimicrob Agents Chemother; 2001 Jan; 45(1):303-5. PubMed ID: 11120983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
